MedTrace Logo

Safety of Extracellular Vesicles for Burn Wounds

NCT05078385 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2024-11-20

No results posted yet for this study

Summary

Treatment of patients with deep second degree burns of the skin with extracellular vesicles (EV) isolated from bone marrow derived mesenchymal stem cells.

Conditions

  • Burns

Interventions

DRUG

AGLE-102

AGLE-102, bone marrow mesenchymal stem cell derived extracellular vesicles (EVs)

Sponsors & Collaborators

  • Congressionally Directed Medical Research Programs

    collaborator FED

  • Aegle Therapeutics

    lead INDUSTRY

Principal Investigators

  • Carl Schulman, MD · Ryder Trauma Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-10
Primary Completion
2024-09-05
Completion
2024-11-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05078385 on ClinicalTrials.gov